We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Elelyso: A New Therapeutic Option for Patients with Gaucher Disease

Product News   May 11, 2012

 
Elelyso: A New Therapeutic Option for Patients with Gaucher Disease
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Phase I/II Clinical Trial of COVID-19 Vaccine Begins

Product News

Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX‑CoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology.

READ MORE

Positive Interim Phase 1 Data for mRNA Vaccine Against SARS-CoV-2

Product News

Moderna, Inc. announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

READ MORE

Funding Boost for UK Vaccine Programme

Product News

The UK Government has announced £65.5 million of new funding for the vaccine being developed at the University of Oxford as coronavirus vaccine trials accelerate.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE